ELI LILLY & CO
LLYNYSETrading Snapshot
- Day Range
- $1341.88 β $1372.05
- 52-Week Range
- $850.51 β $1,475.25
- Volume (shares)
- 3,540,083
- Avg Volume (shares)
- β
- Shares Outstanding
- 940.8M
- Next Earnings
- 2027-02-02
Fundamentals Snapshot
- Annual Revenue
- $65.18B
- Last Q Revenue
- $24.40B
- P/E Ratio
- 46.1
- P/S Ratio
- 14.7x
- EPS (TTM)
- $30.81
- Dividend Yield
- 0.47%
- Dilution (1yr)
- β0.6%
ELI LILLY & CO
LLYAbout ELI LILLY & CO
Pharma with leading GLP-1 franchise (Mounjaro, Zepbound).
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Eli Lilly's Obesity Pipeline Is Getting Crowded. That's Great News for Investors
Zepbound and Foundayo currently anchor Eli Lilly's obesity lead. Retatrutide and EloraTZP outperformed Zepbound in weight-loss trials, though not yet in head-to-head Phase 3 studies.

$1,000 Invested in Eli Lilly 5 Years Ago Is Now Worth Over $5,000. Could It Soar That Much Again by 2031?
Eli Lilly has seen revenue explode higher in recent years thanks to its dominance in the weight loss drug market. Its weight loss portfolio drove double-digit revenue growth in the recent quarter.

Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight
Zepbound helped adolescents lose substantial weight and improve key health measures in a clinical trial. Younger patients could open a meaningful new market for Eli Lilly's obesity franchise.

My Top Dividend Growth Picks In Each GICS Sector (November 2026)
I present my top dividend growth picks in each GICS sector based on quality scores. The sector winners would have returned 144% over five years, versus SPY's 63%. Royal Gold is my standout value candidate. It meets all m

Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
Lilly and Pfizer offer contrasting growth stories driven by blockbuster drugs, expanding pipelines and strategic investments.

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq. Eli Lilly is seeing explosive revenue growth driven by its dominant presence in the metabolic health market.